Emotional distress and quality of life during folinic acid, fluorouracil, and oxaliplatin in colorectal cancer patients with and without chemotherapy-induced peripheral neuropathy: A cross-sectional study

摘要

When the 5-fluorouracil, leucovorin, and oxaliplatin ( FOLFOX ) chemotherapy regimen is used to treat colorectal cancer (CRC), chemotherapy-induced peripheral neuropathy ( CIPN ) caused by oxaliplatin can substantially affect quality of life (QOL) in the CRC patients. This study compared emotional distress and QOL during FOLFOX in CRC patients with and without CIPN symptoms. This cross-sectional, descriptive, and comparative study recruited 68 CRC patients receiving FOLFOX at a local teaching hospital and at a medical center in southern Taiwan. Self-reported structured questionnaires (oxaliplatin-associated neuropathy questionnaire, profile of mood states short form, and the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire, Core 30, version 3.0) were used for 1-time data collection. The Chi-square test, Fisher exact test, and Mann–Whitney U test were used to analyze data, and a P -value .05 was considered statistically significant. The CIPN group had 45 (66.2%) patients, and the non- CIPN group had 23 (33.8%) patients. The 5 most common symptoms were coldness-related burning sensation or discomfort in the upper limbs, numbness in the upper limbs, tingling in the upper limbs, impairment of vision, and discomfort in the throat. The CIPN group had more females ( P = .013), a more advanced stage of CRC ( P = .04) and a higher chemotherapy dosage ( P = .006). The 2 groups did not significantly differ in anxiety ( P = .065) or depression ( P = .135). Compared to the non- CIPN group, the CIPN group had significantly lower functioning ( P = .001) and global health status ( P .001) and significantly more symptoms ( P .001). The CIPN group had significantly lower QOL compared to the non- CIPN group. However, the CIPN group did not have lower emotional distress compared to the non- CIPN group. The results of this study demonstrate the need for in-service courses specifically designed to train health professionals in assessing and managing CIPN symptoms to improve QOL in CRC patients receiving FOLFOX .